Преглед према Аутор
Herbst, Roy S
Приказ резултата 1 до 5 од 5
| Година | Наслов | Аутор(и) | Тип резултата | Мп-кат. |
| 2020 | Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC | Herbst, Roy S; ...; Andric, Zoran G; ...; (broj, koautora 22) | Научни чланак | 21aM21a - Рад у међ. часопису изузетних вредности |
| 2020 | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 | Herbst, Roy S; ...; Andric, Zoran G; ...; (broj, koautora 21) | Конференцијски рад | |
| 2019 | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study | Herbst, Roy S; ...; Andric, Zoran G; ...; (broj, koautora 20) | Конференцијски рад | |
| 2020 | Impower110: Interim Overall Survival (OS) Analysis of a Phase Iii Study of Atezolizumab (Atezo) Monotherapy Vs Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Treatment in PD-L1-Selected NSCLC | Herbst, Roy S; ...; Andric, Zoran G; ...; (broj, koautora 20) | Конференцијски рад | |
| 2021 | IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1-Selected NSCLC | Herbst, Roy S; ...; Andric, Zoran G; ...; (broj, koautora 20) | Конференцијски рад | |